PRICE T ROWE ASSOCIATES INC /MD/ - ALLOGENE THERAPEUTICS INC ownership

ALLOGENE THERAPEUTICS INC's ticker is ALLO and the CUSIP is 019770106. A total of 178 filers reported holding ALLOGENE THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.70 and the average weighting 0.1%.

Quarter-by-quarter ownership
PRICE T ROWE ASSOCIATES INC /MD/ ownership history of ALLOGENE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$7,632
-71.2%
2,407,347
-54.8%
0.00%
-75.0%
Q2 2023$26,498
-15.3%
5,331,400
-15.8%
0.00%
-20.0%
Q1 2023$31,273
-16.3%
6,330,304
+6.5%
0.01%
-16.7%
Q4 2022$37,374
-99.9%
5,941,797
+0.6%
0.01%
-40.0%
Q3 2022$63,800,000
+0.7%
5,907,316
+6.3%
0.01%
+25.0%
Q2 2022$63,375,000
+63.0%
5,559,176
+30.3%
0.01%
+100.0%
Q1 2022$38,870,000
-19.9%
4,266,735
+31.2%
0.00%0.0%
Q4 2021$48,513,000
-56.5%
3,251,528
-25.1%
0.00%
-63.6%
Q3 2021$111,512,000
+20.9%
4,338,991
+22.7%
0.01%
+22.2%
Q2 2021$92,198,000
-24.4%
3,535,184
+2.3%
0.01%
-25.0%
Q1 2021$122,023,000
+35.8%
3,456,753
-2.9%
0.01%
+33.3%
Q4 2020$89,849,000
-33.4%
3,559,793
-0.5%
0.01%
-43.8%
Q3 2020$134,914,000
-16.9%
3,577,684
-5.6%
0.02%
-20.0%
Q2 2020$162,321,000
+278.8%
3,790,786
+72.0%
0.02%
+185.7%
Q1 2020$42,856,000
-33.2%
2,204,534
-10.8%
0.01%
-12.5%
Q4 2019$64,184,000
-6.5%
2,470,510
-1.9%
0.01%
-20.0%
Q3 2019$68,646,000
+1.3%
2,518,672
-0.2%
0.01%0.0%
Q2 2019$67,740,000
-4.5%
2,522,906
+0.1%
0.01%0.0%
Q1 2019$70,949,000
+7.7%
2,519,508
+0.3%
0.01%
-9.1%
Q4 2018$65,888,0002,511,9980.01%
Other shareholders
ALLOGENE THERAPEUTICS INC shareholders Q4 2021
NameSharesValueWeighting ↓
Vida Ventures Advisors, LLC 1,798,163$5,700,1778.82%
Wildcat Capital Management, LLC 1,920,787$6,088,8952.44%
TPG GP A, LLC 18,716,306$59,330,6901.02%
EcoR1 Capital, LLC 4,488,200$14,227,5940.48%
CROSSPOINT FINANCIAL, LLC 12,000$38,0400.40%
Coastal Bridge Advisors, LLC 406,847$1,289,7050.35%
CAXTON ASSOCIATES LP 480,104$1,521,9300.21%
Woodline Partners LP 5,313,915$16,845,1110.20%
Rhenman & Partners Asset Management AB 300,000$951,0000.10%
Navalign, LLC 75,365$238,9070.09%
View complete list of ALLOGENE THERAPEUTICS INC shareholders